Multicentre, Double-Blind Study Comparing 0.5mg Dutasteride vs. Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer.

Trial Profile

Multicentre, Double-Blind Study Comparing 0.5mg Dutasteride vs. Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms AVIAS
  • Most Recent Events

    • 13 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 13 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 31 Jul 2012 Planned end date changed from 1 Mar 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top